🔥Telegram İfşa

Brittany, a young Mom & never-smoker, was diagnosed w/ #RET+ #lungcancer at 36. #IAmRETPositive #lcsm youtube.com/watch?v=e5bMyN…

Don’t miss out! My colleague Tejas Patil presenting his exciting work on early MET bypass signaling in ALK and RET driven NSCLC. He is also an CU Cancer Center Rising Star! LUNGevity Foundation ALK Positive RETpositive #LCSM #AACR24

📌Did You Know? 📌The FIRST International Pregnancy and Lung Cancer Registry has been created by the #FlorezLab, to understand the disease in this special population. 📌Anyone, ANYWHERE in the world can enter their own cases Email us📩: [email protected]

Big news for European #cancer #patients 🇪🇺 Selpercatinib has been approved by EU Medicines Agency for advanced RET fusion positive solid tumours 🎯 This marks the 2nd tumour agnostic, biomarker-driven approval in the EU. #PrecisionMedicine OncoAlert 🚨 ec.europa.eu/health/documen…

Great news! biospace.com/article/releas…

In our latest blog, Dr. Hideo Watanabe (Icahn School of Medicine at Mount Sinai) shares updates on what is happening in his lab that could improve the long-term effectiveness of targeted therapy treatment for #lungcancer patients. Read here: bit.ly/3Qui7hI RETpositive

Thank you Dr. Watanabe, Lungevity and the patient community who helped fund this important research. #patientadvocacy #lcsm LUNGevity Foundation

Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review frontiersin.org/journals/oncol…

Our latest blog features Tejas Patil as he highlights the importance of teamwork in #lungcancerresearch and why his work to study #MET & #EGFR signaling pathways may help us overcome drug resistance in multiple types of lung cancer. lungevity.org/blogs/kicking-… #RET #lcsm

Every year since 2018 we have gathered 5 or more year survivors of lung cancer together at CU to show others that hope has a face. This is the May 11th 2024 gathering. Rock on!

At #ASCO24, see our poster presentation examining a selective RET inhibitor in patients with non-MTC RET-mutated tumors. Results from the LIBRETTO-001 study: e.lilly/3x3gbpI #CancerResearch #PrecisionMedicine

#ASCO24 Rapid Oral Presentation: Safety and efficacy of a selective RET inhibitor in pediatric and adolescent patients with RET-altered solid tumors. Results from the phase 1/2 LIBRETTO-121 study: e.lilly/4dVE5nU #CancerResearch #PrecisionMedicine

Excellent discussion from Lecia Sequist, MD, MPH, FASCO We can’t do the same for all oncogene driven tumours. Worth considering if there is CNS penetration and low tox. Access will be issue. #LCSM #ASCO24

Very important questions regarding management of other oncogene addicted nsclc in light of this data!

At #ASCO24, we’re sharing intracranial outcomes data from LIBRETTO-431, a phase 3 study investigating front-line use of a selective RET inhibitor in patients with RET fusion+ advanced #NSCLC. Read the results here: e.lilly/4aB9ARm #CancerResearch #LungCancer #LCSM

‼️ #ASCO24 simultaneous publication by Williams et al: CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced #NSCLC: brnw.ch/21wKnSd

Proud to announce our collaboration with @23andme + 19 lung cancer advocacy groups to advance the Lung Cancer Genetics Study. US #lungcancer survivors: pls join & help us drive life-saving scientific discoveries. #lcsm 23andme.com/lung-cancer/?u…